Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an ...

Research led by Mirvie Inc. has discovered a molecular signal in blood samples that can predict preeclampsia and related ...

A new systematic review identifies 17 modifiable risk factors shared by stroke, dementia, and late-life depression — offering ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

My 15-year-old cat looms over me where I lie in bed, pretending I don’t see her. “Meow,” she says plaintively. I gently shrug ...